CN

CN

News

Company News Industry News

Company News

MediLink Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of YL217

July 2, 2025 – MediLink Therapeutics, a clinical-stage biotechnology company, today announced that the first patient has been enrolled and dosed in China in the Global Phase I clinical trial of YL217. YL217 is a CDH17-targeting antibody-drug conjugate (ADC) based on MediLink’s proprietary TMALIN® technology platform.

2025-07-03

MediLinks Appoints Dr. Weichang Zhou as Chief Technology Officer

2025-07-01

MediLink Announces YL201 Granted Breakthrough Therapy Designation by FDA

June 23, 2025 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to YL201 for the treatment of small cell lung cancer (SCLC). YL201 is an investigational B7H3-targeted antibody drug conjugate (ADC) developed based on MediLink’s proprietary TMALIN® (Tumor Microenvironment Activable LINker) technology platform.

2025-06-24

Expanded Access Policy

MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) is a biopharmaceutical company focusing on the development of innovative medicines and bringing new therapies for patients with cancer. We conduct clinical trials to evaluate the safety and efficacy of investigational product candidates. Clinical trials are controlled research studies in humans designed to determine if an investigational product candidate is safe and effective. MediLink encourages awareness of and participation in our clinical trials. For information regarding MediLink-sponsored clinical trials, please visit clinicaltrials.gov

2025-07-02Learn more

MediLink Therapeutics to Present Preclinical Data for Latest Innovations at AACR 2025

March 25, 2025- MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, announces the presentation of preclinical data for two innovative ADC programs (YL217, a CDH17-targeting ADC, and YL242, a VEGF-targeting ADC) and its next-generation dual payload platform at the upcoming AACR Annual Meeting 2025. AACR will be held in Chicago, US April 25-30.

2025-03-26Learn more

MediLink’s YL217 received FDA Clearance of IND Application

February 1, 2025 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for YL217, an investigational antibody-drug conjugate (ADC) developed by MediLink. YL217 is the 11th ADC candidate entering into clinical stage developed based on MediLink’s proprietary TMALIN® technology platform.

2025-02-02Learn more

YL201 Received Another Breakthrough Therapy Designation for the Treatment of R/M NPC

January 20, 2025 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, announced that the Center for Drug Evaluation (CDE) granted Breakthrough Therapy Designation to YL201, for the treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). Previously, the Breakthrough Therapy Designation was also granted for YL201 by the CDE for the treatment of recurrent small cell lung cancer.

2025-01-20Learn more

MediLink Announces Collaboration with AstraZeneca to Explore the Combinational Potential of YL201 and Imfinzi®

Suzhou, China, Jan 14, 2025 -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, announced that a clinical collaboration has been established with AstraZeneca to explore the therapeutic potential in solid tumors, of the combination of MediLink's B7-H3-targeting antibody-drug conjugate (ADC) YL201 and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® ( durvalumab).

2025-01-14Learn more

MediLink Therapeutics Announces Strategic Partnership with Zai Lab to Develop a Novel LRRC15 Antibody-Drug Conjugate

SUZHOU, SHANGHAI and CAMBRIDGE, Mass., Jan 10, 2025 -- MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) today announced a new strategic collaboration and worldwide license agreement with Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) to use MediLink’s TMALIN® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab.

2025-01-10Learn more
1 2 3 4 5 6